These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 23817375)
1. Effect of prednisone on the pharmacokinetics of the integrase inhibitor dolutegravir. Song IH; Borland J; Chen S; Savina P; Peppercorn AF; Piscitelli S Antimicrob Agents Chemother; 2013 Sep; 57(9):4394-7. PubMed ID: 23817375 [TBL] [Abstract][Full Text] [Related]
2. Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects. Song I; Borland J; Chen S; Peppercorn A; Wajima T; Piscitelli SC Antimicrob Agents Chemother; 2014 Nov; 58(11):6696-700. PubMed ID: 25155604 [TBL] [Abstract][Full Text] [Related]
3. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744. Ford SL; Gould E; Chen S; Margolis D; Spreen W; Crauwels H; Piscitelli S Antimicrob Agents Chemother; 2013 Nov; 57(11):5472-7. PubMed ID: 23979733 [TBL] [Abstract][Full Text] [Related]
4. No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects. Ross LL; Song IH; Arya N; Choukour M; Zong J; Huang SP; Eley T; Wynne B; Buchanan AM BMC Infect Dis; 2016 Jul; 16():347. PubMed ID: 27450277 [TBL] [Abstract][Full Text] [Related]
5. Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation. Song I; Weller S; Patel J; Borland J; Wynne B; Choukour M; Jerva F; Piscitelli S Eur J Clin Pharmacol; 2016 Jun; 72(6):665-70. PubMed ID: 26898568 [TBL] [Abstract][Full Text] [Related]
6. Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir. Song I; Borland J; Chen S; Guta P; Lou Y; Wilfret D; Wajima T; Savina P; Peppercorn A; Castellino S; Wagner D; Hosking L; Mosteller M; Rubio JP; Piscitelli SC Eur J Clin Pharmacol; 2014 Oct; 70(10):1173-9. PubMed ID: 25146692 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment. Weller S; Borland J; Chen S; Johnson M; Savina P; Wynne B; Wajima T; Peppercorn AF; Piscitelli SC Eur J Clin Pharmacol; 2014 Jan; 70(1):29-35. PubMed ID: 24096683 [TBL] [Abstract][Full Text] [Related]
8. Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women. Adams JL; Patterson KB; Prince HM; Sykes C; Greener BN; Dumond JB; Kashuba AD Antivir Ther; 2013; 18(8):1005-13. PubMed ID: 23899439 [TBL] [Abstract][Full Text] [Related]
9. Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing. Greener BN; Patterson KB; Prince HM; Sykes CS; Adams JL; Dumond JB; Shaheen NJ; Madanick RD; Dellon ES; Cohen MS; Kashuba AD J Acquir Immune Defic Syndr; 2013 Sep; 64(1):39-44. PubMed ID: 23945251 [TBL] [Abstract][Full Text] [Related]
10. [Pharmacokinetics and safety of dolutegravir in healthy Japanese subjects]. Wajima T; Koshiba T; Ohno K; Nishimura Y; Kobayashi H; Yoshida N; Nagashima M; Fujiwara T Jpn J Antibiot; 2013 Feb; 66(1):1-7. PubMed ID: 23777012 [TBL] [Abstract][Full Text] [Related]
11. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study). Waitt C; Orrell C; Walimbwa S; Singh Y; Kintu K; Simmons B; Kaboggoza J; Sihlangu M; Coombs JA; Malaba T; Byamugisha J; Amara A; Gini J; Else L; Heiburg C; Hodel EM; Reynolds H; Mehta U; Byakika-Kibwika P; Hill A; Myer L; Lamorde M; Khoo S PLoS Med; 2019 Sep; 16(9):e1002895. PubMed ID: 31539371 [TBL] [Abstract][Full Text] [Related]
12. Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir. Johnson M; Borland J; Chen S; Savina P; Wynne B; Piscitelli S Br J Clin Pharmacol; 2014 Nov; 78(5):1043-9. PubMed ID: 24838177 [TBL] [Abstract][Full Text] [Related]
13. A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir. Anderson MS; Khalilieh S; Yee KL; Liu R; Fan L; Rizk ML; Shah V; Hussaini A; Song I; Ross LL; Butterton JR Clin Pharmacokinet; 2017 Jun; 56(6):661-669. PubMed ID: 27699622 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of Generic Pediatric Dolutegravir Dispersible Tablet in Thai Young Children Living With HIV Weighing Below Twenty Kilograms. Rungsapphaiboon A; Wacharachaisurapol N; Anugulruengkitt S; Sirikutt P; Phasomsap C; Tawan M; Saisaengjan C; Na Nakorn Y; Paiboon N; Songtaweesin WN; Tawon Y; Cressey TR; Puthanakit T; Pediatr Infect Dis J; 2024 Aug; 43(8):789-794. PubMed ID: 39018516 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin. Wang X; Cerrone M; Ferretti F; Castrillo N; Maartens G; McClure M; Boffito M Int J Antimicrob Agents; 2019 Aug; 54(2):202-206. PubMed ID: 31002950 [TBL] [Abstract][Full Text] [Related]
16. Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine. Walimbwa SI; Lamorde M; Waitt C; Kaboggoza J; Else L; Byakika-Kibwika P; Amara A; Gini J; Winterberg M; Chiong J; Tarning J; Khoo SH Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30420479 [TBL] [Abstract][Full Text] [Related]
17. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Song I; Borland J; Chen S; Patel P; Wajima T; Peppercorn A; Piscitelli SC Antimicrob Agents Chemother; 2012 Mar; 56(3):1627-9. PubMed ID: 22183173 [TBL] [Abstract][Full Text] [Related]
18. Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572. Song I; Borland J; Chen S; Lou Y; Peppercorn A; Wajima T; Min S; Piscitelli SC Br J Clin Pharmacol; 2011 Jul; 72(1):103-8. PubMed ID: 21342217 [TBL] [Abstract][Full Text] [Related]
19. Relative bioavailability of a paediatric granule formulation of the HIV integrase inhibitor dolutegravir in healthy adult subjects. Patel P; Song I; Borland J; Chen S; Peppercorn A; Wajima T; Funaki T; Fujita N; Hughes J; Piscitelli S Antivir Ther; 2014; 19(3):229-33. PubMed ID: 24275098 [TBL] [Abstract][Full Text] [Related]
20. Dolutegravir does not affect methadone pharmacokinetics in opioid-dependent, HIV-seronegative subjects. Song I; Mark S; Chen S; Savina P; Wajima T; Peppercorn A; Bala U; Geoffroy P; Piscitelli S Drug Alcohol Depend; 2013 Dec; 133(2):781-4. PubMed ID: 24018316 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]